Cardiff Oncology, Inc.
CRDFDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How CRDF's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Onvansertib | Phase 2 | Colorectal Cancer | - | - |
Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Frequently asked questions
What is in Cardiff Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Cardiff Oncology, Inc.'s (CRDF) pipeline across Phase 2. Its lead program is Onvansertib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiff Oncology, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cardiff Oncology, Inc. (CRDF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CRDF biotech catalysts?→
Add CRDF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiff Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.